Welcome to our dedicated page for Estrella Immunopharma SEC filings (Ticker: ESLAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Estrella Immunopharma, Inc. (ESLAW) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s U.S. regulatory disclosures in one place. Estrella is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies, with lead candidate EB103 in a Phase I/II trial for relapsed or refractory B-cell non-Hodgkin lymphoma and pipeline candidate EB104 targeting both CD19 and CD22.
Although specific filings are not listed in the provided materials, Estrella references a shelf registration statement on Form S-3 that was declared effective by the U.S. Securities and Exchange Commission in connection with a registered direct offering of common stock and pre-funded warrants. The company also notes a concurrent private placement of common warrants and a registration rights agreement to file one or more registration statements covering the resale of shares issuable upon exercise of those warrants.
On this page, users can access Estrella’s registration statements, prospectus supplements, and related offering documents as they become available through EDGAR. For a company at Estrella’s stage, these filings are useful for understanding its capital structure, terms of warrants and other securities, and the framework under which it raises funds to support clinical development of EB103 and EB104.
Stock Titan enhances these documents with AI-powered summaries that explain key sections of lengthy filings in plain language, highlight important terms in registration statements, and surface relevant information about securities such as ESLAW warrants. Real-time updates from EDGAR ensure that new Estrella filings, including future registration statements or other disclosures, can be reviewed quickly with contextual AI insights.
Estrella Immunopharma, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the registration statement unchanged and focuses on updating the list of exhibits.
The filing itemizes corporate documents such as the amended and restated charter and bylaws, various merger and financing agreements, equity incentive plans, employment agreements, and a warrant agreement, largely incorporated by reference from earlier filings. It also includes the legal opinion from Winston & Strawn LLP, consents from current and former auditors, XBRL-related exhibits, and powers of attorney.
The amendment is signed on behalf of Estrella Immunopharma by Chief Executive Officer Cheng Liu and lists the company’s principal officers and directors, confirming their authorization of the registration statement.
FAQ
What is the current stock price of Estrella Immunopharma (ESLAW)?
